[The role of small bowel microflora in the development of secondary lactase deficiency and the possibilities of its treatment with probiotics].

AIM: To estimate the incidence of secondary lactase deficiency (SLD) in patients with postinfectious irritable bowel syndrome (PIBS) and the value of the small bowel microflora in its development and to elaborate treatment options for SLD. SUBJECTS AND METHODS: One hundred and thirty-eight patients with PIBS, including 112 (81.2%) women and 26 (18.8%) men, were examined. The patients' mean age was 33.9 +/- 9.1 years. The duration of the disease was 2.6 +/- 1.4 years. Lactase deficiency (LD) was diagnosed using the color scale to test biopsy specimens from the duodenal retrobulbar region. The bacterial overgrowth syndrome (BOS) was identified by a 2-hour lactulose (20 ml) hydrogen breath test. Sixty patients with moderate SLD were randomized to 2 groups: 1) 41 patients received basic therapy (mesim forte as one tablet t.i.d., no-spa, 40 mg, t.i.d.) and combined probiotic bifiform (Ferrosan) containing Bifidobacterium longum 107, Enterococcus faecium 107 as one capsule t.i.d. for 14 days. Group 2 patients (n = 19) had basic therapy in combination with placebo. RESULTS: SLD was detected in 59.4% of the patients with PIBS, including 43.5 and 15.9% with moderate and severe forms, respectively. In all cases, SLD was accompanied by BOS in the small bowel lumen, as confirmed by the results of a hydrogen breath test [101 +/- 37 ppm (a normal value of < 20 ppm)]. After a 14-day course of therapy with the combined probiotic bifiform, restoration of eubiosis in the small bowel lumen was achieved in 70.8% of the patients, as shown by the lesser degree of BOS (86.9 +/- 40.9 and 17.4 +/- 6.6 ppm before and after treatment, respectively; p < 0.01) and by normalization of the lactase test (p < 0.01). In the comparative placebo group, 68.4% showed no clear positive changes, SLD and BOS remained. CONCLUSION: The changes in the small bowel intraluminal microflora, which developed after prior intestinal infection, played a great role in the development of SLD. Bifiform belongs to the currently available probiotics and may be recommended to correct SLD in patients with PIBS resulting from the impaired microbiota of the small bowel and to prevent BOS.

[Cholagenic diarrhea is a type of postcholescystectomy syndrome].

AIM: To study the role of biliary acids (BAs) in the pathogenesis of chronic diarrhea (CD) in patients undergoing cholecystectomy (CE). SUBJECTS AND METHODS: Twenty-five patients with post-CE diarrhea were examined. A comparison group consisted of 11 patients with diarrhea-predominant irritable bowel syndrome (IBS). The results of an examination of 15 healthy individuals were taken as normal values. Daily fecal BAs were determined by an enzyme spectrophotometric technique. RESULTS: In the patients after CE, daily fecal BA losses were found to be thrice as large as that in the healthy individuals. In the comparison group of patients with IBS, fecal bile excretion was not greater than the normal values. Stool normalization with a simultaneous decrease in fecal BA losses was seen in 92% of the post-CE patients receiving a course of therapy with adsorbents and astringents. CONCLUSION: Post-CE CD is a type of postcholescystectomy syndrome.

[The role of bile acids in the pathogenesis of chronic diarrhea].

Chronic diarrhea syndrome results from excess colonic bile acids. Fibroblast growth factor 19 (FGF19), produced in the ileum is response to bile acid absorption, regulates hepatic bile acids synthesis. Bile acid malabsorption can be found in various gastrointestinal conditions: the greatest losses bile acids with excrements were marked at patients with surgical resection of terminal ileum. The maintenance in daily colonic excess bile at patients with postholecystectomy exceed more than in three times the indicators noted at control subjects, but at the patients with irritable bowel sindrom did not exceed the norm. Effective remedies in treatment chologenic diarrhea were bile acid sequestran.

[Lactase deficiency in patients with postinfectious irritable bowel syndrome and the role of intestinal microflora in its development].

PURPOSE: to define the frequency of secondary lactase deficiency (SLD) in patients with postinfectious IBS and to develop therapy for the correction of mild SLD in adult patients. METHODS AND MATERIALS: In this study, 138 patients (the mean age - 33.9 +/- 9.09; F/M - 112/26) with postinfectious IBS were analyzed concerning lactase deficiency. All patients underwent intestinal endoscopy with biopsies from the mucosa of the descending duodenum in order to determine lactase deficiency twice before and after therapy. To diagnose small intestinal bacterial overgrowth (SIBO) all patients underwent lactulose breath test during 2 hours. RESULTS: SLD was detected in 59.4% of patients with postinfectious IBS. Mild SLD was determined in 43.5% of patients, and severe SLD - in 15.9% of patients. SLD in all cases was accompanied by SIBO (the mean level of lactulose breath test was 101 +/- 37 ppm, N<20 ppm). In group patients who took the probiotic during 14 days in 70.8% of patients recovering of lactose metabolism in the small intestine and decreasing of the intensity of clinical symptoms were registered. The decrease of the lactulose breath test level (86.9 +/- 40.9 ppm; 17.4 +/- 6.6 ppm; p<0.01) and negative LQT (p<0.01) were registered in the first group. In group patients who took placebo during 14 days there was no positive effect in 68.4% of cases. CONCLUSION: the probiotic Bifiform, composed of Bifidobacterium longum 10(7) and Enterococcus faecium 10(7), demonstrated efficiency in correction of mild SLD in patients with postinfectious IBS and can be used to prevent SIBO.

[Features of chronic pancreatitis in the elderly patients].

The aim of this study was to determine the severity of the exocrine and endocrine insufficiency of the pancreas, HC composition and state of homeostasis in the elderly patients. Was obsercved 76 patients with CP (46 females, 30 males), of whom 20 patients diagnosed alcoholic pancreatitis (AP) aged 30 to 55 years. At 26 patients was marked biliary pancreatitis (BP), age of patients was 35-60 years and at 30 was found involutional pancreatitis (IP) from 60 to 74 years, 15 people (with no signs of lesions of the gastrointestinal tract) consisted the control group. The diagnosis of CP was made on the basis of clinical data, laboratory and instrumental investigations. Depending on the etiology of chronic pancreatitis was revealed a different degree of impairment of exocrine and endocrine functions of pancreas. These changes were more pronounced in patients with AP, which depended on the severity of the disease and the presence of complications. In duodenal bile of patients was significantly progressive decrease in the total content of the HC, which depended on the reduction of the total content of the conjugates. Revealed a qualitative change in HC composition may reduce absorption of exogenous cholesterol in the intestine of patients with CP, and is one of the reasons affecting the state of the exocrine pancreas. These changes are especially pronounced in patients with IP. All patients with CP were observed on blood hypercoagulation, which was accompanied by a decrease in the overall constant blood clotting, increasing content of F, an increase in the index of coagulation and clot elasticity. Especially pronounced these changes were in patients with complicated disease and the elderly patients.

[Autoimmune reaction component in chronic pancreatitis: clinical and experimental study].

UNLABELLED: The study was undertaken to identify the relationship between inflammatory and autoimmune processes in chronic pancreatitis and to determine the prognostic significance of autoantibodies to antigens of acinar cells and hepatocytes, immunoglobulin G1-4. MATERIALS AND METHODS: In 85 patients with CP (43 men, 42 women) were studied autoantibodies to antigens of acinar and liver cells, IgG1-4. Of these, 43 patients HP was characterized by complications (cysts, calcification, pseudotumoral form), 40 patients--HP without complications, 2 patients were diagnosed chronic autoimmune pancreatitis (CAP), confirmed histologically. 20 people-- the control group. Experimental studies on animals, reproduction of acute and chronic pancreatitis. RESULTS: Maximize the level of autoantibodies--32.4 +/- 5.6 U / ml (control--10.5 +/- 2.5 U / ml) (p < or = 0.01), as well as IgG4--24 mg/ml in normal (0.8 +/- 0.08 mg/ml)--was recorded in patients with autoimmune pancreatitis. The average value of autoantibodies--in patients with CP complications: 24.2 +/- 3.8 U/ml (p < or = 0.01). The minimum value of autoantibodies--in patients with CP without complications: 18.6 +/- 2.6 U/ml (p < or = 0.05). CONCLUSION: The course of autoimmune pancreatitis accompanied by an increase of autoantibodies to antigens of acinar and liver cells, as well as serum IgG1-4, especially IgG4, which reflects the intensity of the autoimmune responses in this disease. In addition, the exacerbation of chronic pancreatitis with complications is clearly defined autoimmune component of disease. Experimental studies with preimmunization of animals allogeneic tissues have convincingly demonstrated that the formation of antibodies is not only to the antigens, reflecting the specific characteristics of these tissues, but also to general cell structures of other tissues.

[Autoimmune pancreatitis associated with Shegren syndrome].

In the article presented a clinical case of autoimmune pancreatitis in association with Shegren syndrome.

[Exocrine function of the pancreas at chronic pancreatitis: diagnosis an drug correction].

Estimation of respiratory test with 13C- mixed triglytcherides and gastrointestinal hormones effeciancy for the diagnosis of extrasecretory pancreatic with chronic pancreatitis was the aim of this examination. Test 13C- mixed triglytcherides was examined vercus test with pancreatic elastase of feces (E-1). 45 patients with chronic pancreatitis and 20 patients in 2 control groups were examined. The resuets testify to the lowering of pancreatic exocrine function in the patients with complicated chronic pancreatitis. The levels of E-1 and CPRDF (360) were trustworthy low the patients with complicated chronic pancreatitis versus the patients with chronic pancreatitis without complications and in control groups (p < 0.05). Correlative analysis the levels of E-1 and CPRDF (360) had demonstrated high degrel of results similarity. Persons correlation index was r = 0.64 (p < 0.001). The secretines level after standart breakfast in the patients with chronic pancreatitis was lowering, but was increasing in the healthy persons. Secretine lowering may lead to the bicarbonates secretion lowering. These results testify to the necessity of fermental treatment in the patients with chronic pancreatitis accordingly the pancreatitis stage.

[Antibodies to Helicobacter pylori in gastric diseases].

AIM: To study the count of antibodies to Helicobacter pylori (ABHP), their role in diagnosis and prognosis in gastric diseases (GD). MATERIAL AND METHODS: Enzyme immunoassay (kits from EcoLab and Vektor-Best, Russia) was used to measure serum levels of ABHP (IgG, IgA, IgM+IgG+IgA) in 46 GD patients. RESULTS: It is shown that GD are characterized by a regular rise of serum ABHP which are serological markers of Helicobacter pylori infection. Percentage and absolute value of IgG-HP were the highest (78%, mean titer 1:604 vs control 1:110) as well as (IgM+IgG+IgA) antibodies to CagA-HP (approximately 82%, mean titer 1:160 vs. control 1:10); the level of IgA-HP was elevated by 39%, mean titer 1:442, control 1:120. Elevated levels of IgG-HP reflect intensity of inflammatory processes, IgA-HP--atrophic processes, IgM+IgG+IgA)-CagA-HP--proliferative processes in GD. CONCLUSION: High concentrations of ABHP are a diagnostic criterion of HP infection, reflect intensity of infectious, inflammatory, atrophic and proliferative processes in GD. Long-term persistence of elevated ABHP concentrations is one of the indications for application of antichelicobacter therapy in GD associated with HP while ABHP fall is an additional criterion of efficacy of the treatment.

[Anti-Helicobacter pylori antibodies in cases of stomach polyps].

UNLABELLED: The goal of the study was to study the content of anti-Helicobacter pylori antibodies (at-HP), their diagnostic and prognostic significance for stomach polyps. MATERIALS AND METHODS: The content of anti-Helicobacter antibodies (IgG-HP; IgA-HP; IgM + IgG + IgA-CagA-HP) was determined in the blood serum by way of immune-enzyme analysis of 46 patients with stomach polyps. Such test systems as EcoLab (Elektrostal) and Vector-Best (Novosibirsk) were used. RESULTS: Stomach polyps are accompanied by a regular increase of at-HP--serologic markers of helicobacteriosis content in the blood serum. The most significant increase in terms of percentage and absolute values is the IgG-HP concentration increase (88%, average titre 1: 1060, in the control group--1: 110) and summary (IgM + IgG + IgA) antibodies to CagA-HP (86%, average titre 1 : 180, in the control group 1 : 10), while the IgA-HP level is increased in 46%, average titre 1 : 660, in the control group 1 : 120). The IgG-HP content increase reflects the inflammatory process intensity, IgA-HP--atrophic process intensity, (IgM + IgG + IgA)-CagA-HP--1 intensity of proliferative processes of stomach polyps. CONCLUSION: The at-HP content increase is a diagnostic criterion for helicobacteriosis and reflects the intensity of infectious, inflammatory, atrophic and proliferative processes in cases of stomach polyps. A multiple long-lasting increase of the at-HP concentration may be one of the indications for administering an antihelicobacter stomach polyp therapy including administration before polypectomy.